|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study显示文摘 | Patrick Marcellin Edward Gane Maria Buti Nezam Afdhal William Sievert Ira M Jacobson Mary Kay Washington George Germanidis John F Flaherty Raul Aguilar Schall Jeffrey D Bornstein Kathryn M Kitrinos G Mani Subramanian John G McHutchison E Jenny Heathcote | 2012 | The Lancet2012，，： | 14 |
| 2 | Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010显示文摘 | Rafael Lozano Mohsen Naghavi Kyle Foreman Stephen Lim Kenji Shibuya Victor Aboyans Jerry Abraham Timothy Adair Rakesh Aggarwal Stephanie Y Ahn Mohammad A AlMazroa Miriam Alvarado H Ross Anderson Laurie M Anderson Kathryn G Andrews Charles Atkinson Larry M | 2012 | The Lancet . 2012 (9859)2012，，9859： | 7 |
| 3 | Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010显示文摘 | Rafael Lozano Mohsen Naghavi Kyle Foreman Stephen Lim Kenji Shibuya Victor Aboyans Jerry Abraham Timothy Adair Rakesh Aggarwal Stephanie Y Ahn Mohammad A AlMazroa Miriam Alvarado H Ross Anderson Laurie M Anderson Kathryn G Andrews Charles Atkinson Larry M | 2012 | The Lancet2012，，9859： | 5 |
| 4 | Gastrointestinal perforation in metastatic colorectal cancer patients with peritoneal metastases receiving bevacizumab显示文摘AIM:To investigate the safety and efficacy of adding bevacizumab to first-line chemotherapy in metastatic colorectal cancer patients with peritoneal disease.METHODS:We compared rates of gastrointestinal perforation in patients with metastatic colorectal cancer and peritoneal disease receiving first-line chemotherapy with and without bevacizumab in three distinct cohorts:(1) the AGITG MAX trial(Phase Ⅲ randomised clinical trial comparing capecitabine vs capecitabine and bevacizumab vs capecitabine,bevacizumab and mitomycin C);(2) the prospective Treatment of Recurrent and Advanced Colorectal Cancer(TRACC) registry(any first-line regimen ± bevacizumab);and(3) two cancer centres in New South Wales,Australia [Macarthur Cancer Therapy Centre and Liverpool Cancer Therapy Centre(NSWCC) from January 2005 to Decenber 2012,(any first-line regimen ± bevacizumab).For the AGITG MAX trial capecitabine was compared to the other two arms(capecitabine/bevacizumab and capecitabine/bevacizumab/mitomycin C).In the AGITG MAX trial and the TRACC registry rates of gastrointestinal perforation were also collected in patients who did not have peritoneal metastases.Secondary endpoints included progression-free survival,chemotherapy duration,and overall survival.Time-toevent outcomes were estimated using the Kaplan-Meier method and compared using the log-rank test.RESULTS:Eighty-four MAX,179 TRACC and 69 NSWCC patients had peritoneal disease.There were no gastrointestinal perforations recorded in either the MAX subgroup or the NSWCC cohorts.Of the patients without peritoneal disease in the MAX trial,4/300(1.3%) in the bevacizumab arms had gastrointestinal perforations compared to 1/123(0.8%) in the capecitabine alone arm.In the TRACC registry 3/126(2.4%) patients who had received bevacizumab had a gastrointestinal perforation compared to 1/53(1.9%) in the chemotherapy alone arm.In a further analysis of patients without peritoneal metastases in the TRACC registry,the rate of gastrointestinal perforations was 9/369(2.4%) in the chemotherapy/bevacizumab group and 5/177(2.8%) in the chemotherapy alone group.The addition of bevacizumab to chemotherapy was associated with improved progression-free survival in all three cohorts:MAX 6.9 m vs 4.9 m,HR = 0.64(95%CI:0.42-1.02);P = 0.063;TRACC 9.1 m vs 5.5 m,HR = 0.61(95%CI:0.37-0.86);P = 0.009;NSWCC 8.7 m vs 6.8 m,HR = 0.75(95%CI:0.43-1.32);P = 0.32.Chemotherapy duration was similar across the groups.CONCLUSION:Patients with peritoneal disease do not appear to have an increased risk of gastrointestinal perforations when receiving first-line therapy with bevacizumab compared to systemic therapy alone. | Aflah Roohullah Hui-Li Wong Katrin M Sjoquist Peter Gibbs Kathryn Field Ben Tran Jeremy Shapiro Joe Mckendrick Desmond Yip Louise Nott Val Gebski Weng Ng Wei Chua Timothy Price Niall Tebbutt Lorraine Chantrill | 2015 | World Journal of Gastroenterology2015，21，17： | 3 |
| 5 | 生活方式和饮食因素:预防致死性前列腺癌显示文摘预防致死性前列腺癌是一个重要的公共卫生难题。解决该难题可以改善人们的健康状况,减少罹患该疾病的痛苦。本综述围绕某些与致命性前列腺癌预防有关的生活方式和饮食因素研究进行讨论。我们还对以下行为风险因素的研究进行总结:肥胖和体重变化、体育活动、吸烟状况、抗氧化剂摄入量、维生素D和钙、以及咖啡摄入量。 | Kathryn M Wilson Edward L Giovannucci Lorelei A Mucci | 2012 | Asian Journal of Andrology2012，14，3： | 3 |
| 6 | Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis显示文摘 | Rayner Katey J Sheedy Frederick J Esau Christine C Hussain Farah N Temel Ryan E Parathath Saj van Gils Janine M Rayner Alistair J Chang Aaron N Suarez Yajaira Fernandez-Hernando Carlos Fisher Edward A Moore Kathryn J | 2011 | Journal of Clinical Investigation2011，，7： | 2 |
| 7 | 澳大利亚初级保健诊所新发腰背痛患者的预后:起始队列研究显示文摘目的估计初级保健诊所内新发腰背痛患者的1年预后,并确定其预后因素。设计1年随访队列研究。地点澳大利亚悉尼的初级保健诊所。参试者初级保健诊所接诊的973例非特异性腰背痛连续患者(平均年龄43.3岁,男性54.8%)。该起始队列患者腰背痛时间不足两周,征集自170名全科医生、理疗师或按摩师诊所。主要评估指标参试者完成基线调查问卷后,分别于初次就诊后6周、3个月和21个月时复查评估。评估内容包括:工作恢复情况、功能恢复情况和疼痛消失情况。潜在预后因素与恢复所需时间的关联性用Cox回归建模分析。结果12个月随访率〉97%。基线时工作能力下降的患者半数在14天内恢复了以前的工作状态(95%可信区间11-17天),83%在3个月内恢复。残疾(中位恢复时间31天,25-37天)和疼痛(中位58天,52-63天)则需要较长的时间才能恢复。只有72%的受试者于基线访问后12个月获得完全康复。高龄、赔偿诉讼、疼痛较重、就诊前腰背痛时间较长、就诊前因疼痛活动减少天数较多、抑郁情绪以及预期危险持续与所需恢复时问较长相关。结论在这个急性腰背痛初级保健患者队列,患者的预后并不像临床指南声称的那样乐观。多数患者的恢复缓慢。近三分之一的患者在腰背痛发作后1年尚未恢复。 | Nicholas Henschke Christopher G Maher Kathryn M Refshauge Robert D Herbert Robert G Cumming Jane Bleasel John York Anurina Das James H McAuley 蓝恭涛(译) | 2008 | 英国医学杂志中文版2008，11，6： | 2 |
| 8 | Esophageal squamous cell cancer in a highly endemic region显示文摘AIM: To identify risk factors associated with esophageal cancer in Zambia and association between dietary intake and urinary 8-iso prostaglandin F2α(8-iso PGF2α).METHODS: We conducted a prospective, case control study at the University Teaching Hospital. Subjects included both individuals admitted to the hospital and those presenting for an outpatient upper endoscopy. Esophageal cancer cases were compared to age and sex-matched controls. Cases were defined as patients with biopsy proven esophageal cancer; controls were defined as subjects without endoscopic evidence ofesophageal cancer. Clinical and dietary data were collected using a standard questionnaire, developed a priori. Blood was collected for human immunodeficiency virus(HIV) serology. Urine was collected, and 8-iso PGF2α was measured primarily by enzyme-linked immunosorbent assay and expressed as a ratio to creatinine.RESULTS: Forty five controls(mean age 54.2 ± 15.3, 31 male) and 27 cases(mean age 54.6 ± 16.4, 17 males) were studied. Body mass index was lower in cases(median 16.8) than controls(median 23.2), P = 0.01. Histopathologically, 25/27(93%) were squamous cell carcinoma and 2/27(7%) adenocarcinoma. More cases smoked cigarettes(OR = 11.24, 95%CI: 1.37-92.4, P = 0.02) but alcohol consumption and HIV seropositivity did not differ significantly(P = 0.14 for both). Fruit, vegetables and fish consumption did not differ significantly between groups(P = 0.11, 0.12, and 0.10, respectively). Mean isoprostane level was significantly higher in cases(0.03 ng/mg creatinine) than controls(0.01 ng/mg creatinine)(OR = 2.35, 95%CI: 1.19-4.65, P = 0.014).CONCLUSION: Smoking and isoprostane levels were significantly associated with esophageal cancer in Zambians, but diet, HIV status, and alcohol consumption were not. | Akwi W Asombang Violet Kayamba Mpala M Lisulo Kathryn Trinkaus Victor Mudenda Edford Sinkala Stayner Mwanamakondo Themba Banda Rose Soko Paul Kelly | 2016 | World Journal of Gastroenterology2016，22，9： | 2 |
| 9 | Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010显示文摘 | Rafael Lozano Mohsen Naghavi Kyle Foreman Stephen Lim Kenji Shibuya Victor Aboyans Jerry Abraham Timothy Adair Rakesh Aggarwal Stephanie Y Ahn Mohammad A AlMazroa Miriam Alvarado H Ross Anderson Laurie M Anderson Kathryn G Andrews Charles Atkinson Larry M | 2012 | 2012 (9859)2012，，9859： | 2 |
| 10 | Cellular proteins in influenza virus particles显示文摘 | Shaw Megan L Stone Kathryn L Colangelo Christopher M | 2008 | PLoS pathogens2008，4，10： | 1 |
| 11 | Nitric Oxide, Prostanoids, Cyclooxygenase and Angiogenesis in Colon and Breast cancer 显示文摘 | Richard JB Masaru M Kathryn AR | 2001 | Clin Cancer Res2001，7，11： | 1 |
| 12 | Chemoradiotherapy for locally advanced head and neck cancer:10-year follow-up of the UK Head and Neck(UKHAN1)tri-al显示文摘 | Jeffrey ST Kathryn M Nirmal G | 2010 | Lancet Oncol2010，11，1： | 1 |
| 13 | Comparison of community- and health care-associated methicillin-resistant Staphylococcusaureus infection显示文摘 | Naimi TS Kathryn CS Stephanie M | 2003 | Jama2003，290，22： | 1 |
| 14 | Iron cofactored super oxide dismutase inhibits host responses to Mycobacterium tu berculosis显示文摘 | Kathryn M Michael H Rama K | 2001 | Am J Respir Crit Care Med2001，164，： | 1 |
| 15 | Encouraging Know ledge Sharing: The Role of Organizational Re- ward System s 显示文摘 | Kathryn M Bartol Abhishek Srivastava | 2002 | Journal of Leadership & Organiza- tional Studies2002，9，1： | 1 |
| 16 | Nature显示文摘 | Kathryn A M | 2010 | 468:6432010，468，： | 1 |
| 17 | A multilevel investigation of the motivational mechanisms underlying knowledge sharing and performance显示文摘 | Quigley Narda R Tesluk Paul E Locke Edwin A Bartol Kathryn M | 2007 | Organization Science2007，18，1： | 1 |
| 18 | Effects of fat replacers on sensory properties,color,melting,and hardness of ice cream显示文摘 | Ann M Roland Lance G Phillips Kathryn J | 1999 | Dairy Sci1999，82，： | 1 |
| 19 | Medical students as standardized patients to assess inter-viewing skills for pain evaluation显示文摘 | Brian E Mavis Karen SOgle Kathryn L Lovell&Lisa M Mad-den | 2002 | Medical Education2002，36，： | 1 |
| 20 | Modeling traceability information in soybean value chains显示文摘 | Thakur M Kathryn A M Donnelly | 2010 | Journal of Food Engineering2010，99，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员